Case Reports
doi: 10.1056/NEJMc0706103.
Melanoma complicating treatment with natalizumab for multiple sclerosis
- PMID: 18256405
- DOI: 10.1056/NEJMc0706103
Item in Clipboard
Case Reports
Melanoma complicating treatment with natalizumab for multiple sclerosis
N Engl J Med.
.
No abstract available
Comment in
-
More on melanoma with transdifferentiation.N Engl J Med. 2008 Jul 3;359(1):99; author reply 99-100. doi: 10.1056/NEJMc086089. N Engl J Med. 2008. PMID: 18596284 No abstract available.
Similar articles
-
Melanoma complicating treatment with natalizumab (tysabri) for multiple sclerosis.J Neurol. 2009 Oct;256(10):1771-2. doi: 10.1007/s00415-009-5200-9. Epub 2009 Jul 16. J Neurol. 2009. PMID: 19609591 No abstract available.
-
More on melanoma with transdifferentiation.N Engl J Med. 2008 Jul 3;359(1):99; author reply 99-100. doi: 10.1056/NEJMc086089. N Engl J Med. 2008. PMID: 18596284 No abstract available.
-
Evolution of nevi during treatment with natalizumab: A prospective follow-up of patients treated with natalizumab for multiple sclerosis.Arch Dermatol. 2011 Jan;147(1):72-6. doi: 10.1001/archdermatol.2010.243. Epub 2010 Sep 20. Arch Dermatol. 2011. PMID: 20855675
-
Natalizumab.Drugs Today (Barc). 2006 Oct;42(10):639-55. doi: 10.1358/dot.2006.42.10.1042190. Drugs Today (Barc). 2006. PMID: 17136224 Review.
-
Natalizumab and the role of alpha 4-integrin antagonism in the treatment of multiple sclerosis.Expert Opin Biol Ther. 2007 Jan;7(1):123-36. doi: 10.1517/14712598.7.1.123. Expert Opin Biol Ther. 2007. PMID: 17150024 Review.
Cited by
-
Therapeutic targeting of anoikis resistance in cutaneous melanoma metastasis.Front Cell Dev Biol. 2023 Apr 26;11:1183328. doi: 10.3389/fcell.2023.1183328. eCollection 2023. Front Cell Dev Biol. 2023. PMID: 37181747 Free PMC article. Review.
-
Multiple Sclerosis Treatment and Melanoma Development.Int J Mol Sci. 2020 Apr 22;21(8):2950. doi: 10.3390/ijms21082950. Int J Mol Sci. 2020. PMID: 32331328 Free PMC article. Review.
-
VLA-4 phosphorylation during tumor and immune cell migration relies on its coupling to VEGFR2 and CXCR4 by syndecan-1.J Cell Sci. 2019 Oct 28;132(20):jcs232645. doi: 10.1242/jcs.232645. J Cell Sci. 2019. PMID: 31562188 Free PMC article.
-
Rapid Progression of Low-Grade Cervical Dysplasia into Invasive Cancer during Natalizumab Treatment for Relapsing Remitting Multiple Sclerosis.Case Rep Oncol. 2019 Jan 18;12(1):59-62. doi: 10.1159/000496198. eCollection 2019 Jan-Apr. Case Rep Oncol. 2019. PMID: 31043942 Free PMC article.
-
Monoclonal Antibodies in Multiple Sclerosis: Present and Future.Biomedicines. 2019 Mar 14;7(1):20. doi: 10.3390/biomedicines7010020. Biomedicines. 2019. PMID: 30875812 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
